KR20200002451A - 인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도 - Google Patents

인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도 Download PDF

Info

Publication number
KR20200002451A
KR20200002451A KR1020180075955A KR20180075955A KR20200002451A KR 20200002451 A KR20200002451 A KR 20200002451A KR 1020180075955 A KR1020180075955 A KR 1020180075955A KR 20180075955 A KR20180075955 A KR 20180075955A KR 20200002451 A KR20200002451 A KR 20200002451A
Authority
KR
South Korea
Prior art keywords
seq
antibody
cancer
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020180075955A
Other languages
English (en)
Korean (ko)
Inventor
홍효정
채희수
홍지수
Original Assignee
강원대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강원대학교산학협력단 filed Critical 강원대학교산학협력단
Priority to KR1020180075955A priority Critical patent/KR20200002451A/ko
Priority to CA3104252A priority patent/CA3104252A1/en
Priority to CN201980045545.5A priority patent/CN112689644B/zh
Priority to CN202510003352.0A priority patent/CN119930818A/zh
Priority to CN202410882978.9A priority patent/CN118754985A/zh
Priority to SG11202012680TA priority patent/SG11202012680TA/en
Priority to US17/250,286 priority patent/US11884729B2/en
Priority to AU2019293530A priority patent/AU2019293530B2/en
Priority to KR1020217003012A priority patent/KR102929858B1/ko
Priority to PCT/IB2019/055472 priority patent/WO2020003210A1/en
Priority to JP2020573334A priority patent/JP7527007B2/ja
Priority to MX2020013923A priority patent/MX2020013923A/es
Priority to EP19824775.1A priority patent/EP3841124A4/en
Publication of KR20200002451A publication Critical patent/KR20200002451A/ko
Priority to IL279790A priority patent/IL279790A/en
Priority to JP2023199382A priority patent/JP7740730B2/ja
Priority to US18/407,065 priority patent/US12509513B2/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G01N33/574—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
KR1020180075955A 2018-06-29 2018-06-29 인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도 Pending KR20200002451A (ko)

Priority Applications (16)

Application Number Priority Date Filing Date Title
KR1020180075955A KR20200002451A (ko) 2018-06-29 2018-06-29 인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
AU2019293530A AU2019293530B2 (en) 2018-06-29 2019-06-27 Anti-L1CAM antibodies and uses thereof
JP2020573334A JP7527007B2 (ja) 2018-06-29 2019-06-27 抗ｌ１ｃａｍ抗体及びその使用
CN202510003352.0A CN119930818A (zh) 2018-06-29 2019-06-27 抗l1cam抗体及其用途
CN202410882978.9A CN118754985A (zh) 2018-06-29 2019-06-27 抗l1cam抗体及其用途
SG11202012680TA SG11202012680TA (en) 2018-06-29 2019-06-27 Anti-l1cam antibodies and uses thereof
US17/250,286 US11884729B2 (en) 2018-06-29 2019-06-27 Anti-L1CAM antibodies and uses thereof
CA3104252A CA3104252A1 (en) 2018-06-29 2019-06-27 Anti-l1cam antibodies and uses thereof
KR1020217003012A KR102929858B1 (ko) 2018-06-29 2019-06-27 항-l1cam 항체 및 이의 용도
PCT/IB2019/055472 WO2020003210A1 (en) 2018-06-29 2019-06-27 Anti-l1cam antibodies and uses thereof
CN201980045545.5A CN112689644B (zh) 2018-06-29 2019-06-27 抗l1cam抗体及其用途
MX2020013923A MX2020013923A (es) 2018-06-29 2019-06-27 Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
EP19824775.1A EP3841124A4 (en) 2018-06-29 2019-06-27 ANTI-L1CAM ANTIBODIES AND USES THEREOF
IL279790A IL279790A (en) 2018-06-29 2020-12-27 Anti-l1cam antibodies and uses thereof
JP2023199382A JP7740730B2 (ja) 2018-06-29 2023-11-24 抗ｌ１ｃａｍ抗体及びその使用
US18/407,065 US12509513B2 (en) 2018-06-29 2024-01-08 Anti-L1CAM antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180075955A KR20200002451A (ko) 2018-06-29 2018-06-29 인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20200002451A true KR20200002451A (ko) 2020-01-08

Family

ID=69154626

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020180075955A Pending KR20200002451A (ko) 2018-06-29 2018-06-29 인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
KR1020217003012A Active KR102929858B1 (ko) 2018-06-29 2019-06-27 항-l1cam 항체 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217003012A Active KR102929858B1 (ko) 2018-06-29 2019-06-27 항-l1cam 항체 및 이의 용도

Country Status (6)

Country Link
JP (1) JP7527007B2 (https=)
KR (2) KR20200002451A (https=)
CN (1) CN112689644B (https=)
AU (1) AU2019293530B2 (https=)
CA (1) CA3104252A1 (https=)
SG (1) SG11202012680TA (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240091226A (ko) * 2021-11-03 2024-06-21 큐론 바이오파마슈티칼 (상하이) 컴퍼니, 리미티드 신규 항 l1cam 항체
CN115078738A (zh) * 2022-06-30 2022-09-20 复旦大学 一种l1cam蛋白n979位点特异性核心岩藻糖基化的抑制剂的应用
TW202417057A (zh) * 2022-10-26 2024-05-01 大陸商同潤生物醫藥(上海)有限公司 人源化的l1cam抗體藥物偶聯物
EP4615580A1 (en) * 2022-11-09 2025-09-17 CIS Biopharma AG Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
CN118725118B (zh) * 2024-09-02 2024-11-22 北京凯祥弘康生物科技有限公司 抗人l1cam蛋白的抗体4d3
CN118725119B (zh) * 2024-09-02 2024-11-19 北京凯祥弘康生物科技有限公司 一种抗l1cam蛋白的抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114550A1 (en) 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
KR101501736B1 (ko) * 2008-12-05 2015-03-12 한국생명공학연구원 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용
KR102058381B1 (ko) * 2012-08-24 2019-12-24 강원대학교산학협력단 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
WO2014077648A1 (ko) 2012-11-16 2014-05-22 강원대학교산학협력단 인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도

Also Published As

Publication number Publication date
AU2019293530A1 (en) 2021-01-21
CN112689644A (zh) 2021-04-20
CA3104252A1 (en) 2020-01-02
CN112689644B (zh) 2025-01-28
SG11202012680TA (en) 2021-01-28
KR102929858B1 (ko) 2026-02-26
JP7527007B2 (ja) 2024-08-02
KR20210042091A (ko) 2021-04-16
JP2021529776A (ja) 2021-11-04
AU2019293530B2 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
US20210347908A1 (en) Novel anti-sirpa antibodies
KR20200002451A (ko) 인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
IL300760A (en) Anti-ROR1 antibodies and related bispecific binding proteins
CN113906052A (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
KR102250234B1 (ko) Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도
CA3074524A1 (en) Novel anti-cd19 antibodies
WO2023227062A1 (en) Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
KR20240025513A (ko) 신규 항-cd276 항체 및 이의 용도
TW202348630A (zh) 新穎抗ｃｄ３抗體及其用途
CA3227854A1 (en) Novel anti-sirpa antibodies
US20240270839A1 (en) Novel anti-claudin18 antibodies
WO2019179389A1 (en) Novel anti-egfr antibody polypeptide
CN117801106A (zh) 抗pd-1抗体及其用途
EP4613774A1 (en) Single domain antibody targeting human ror1
US20240317880A1 (en) Epithelial Cadherin-Specific Antibodies
TW202542184A (zh) 與ｃｄ３及ｌｉｌｒｂ４結合之新穎抗體及其用途
HK40095347A (zh) 上皮钙黏素特异性抗体
CN119816519A (zh) 抗ror1抗体、包含其的双特异性抗体及其用途
CN116120461A (zh) 新型抗药抗体以及其用途
HK40076539B (zh) 结合人和猴cd3的抗体及其应用
HK40097196A (zh) 新型抗cldn18抗体

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1204 Withdrawal of earlier application forming a basis of a priority claim

St.27 status event code: N-1-6-B10-B12-nap-PC1204

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000